查詢結果分析
來源資料
相關文獻
- Experience with Ifosfamide and Etoposide Combination Chemotherapy in Extensive-Disease Small-Cell Lung Cancer
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 小細胞肺癌的治療
- 非小細胞肺癌的治療
- Importance of Fiberoptic Bronchoscopy Before and During Chemotherapy for Small cell Carcinoma of the Lung in the Evaluation of Complete Remission
- 晚期非小細胞肺癌之化學治療
- Topotecan(Hycamtin)--治療卵巢癌與小細胞肺癌有新的選擇
- CA405之基因療法合併化學抗癌藥物對肺癌細胞之作用效果評估與機轉的探討(2)
頁籤選單縮合
題 名 | Experience with Ifosfamide and Etoposide Combination Chemotherapy in Extensive-Disease Small-Cell Lung Cancer=使用Ifosfamide和Etoposide治療廣佈期小細胞肺癌的經驗 |
---|---|
作 者 | 吳銘芳; 彭瑞鵬; 陳育民; 劉敏; 楊淑玲; 彭汪嘉康; | 書刊名 | 中華醫學雜誌 |
卷 期 | 60:2 1997.08[民86.08] |
頁 次 | 頁67-73 |
分類號 | 415.468 |
關鍵詞 | 廣佈期; 小細胞肺癌; Extensive-disease; Ifosfamide; Small-cell lung cancer; |
語 文 | 英文(English) |
中文摘要 | 背景:Ifosfamide是cyclophosphamide的同質異構物,用來治療肺癌,睪丸癌,淋巴瘤,肉瘤,皆有顯著的效果,有的報告甚至優於cyclophosphamide。本文報告我們使用ifosfamide和etoposide治療廣佈期小細胞肺癌病人的初步臨床經驗。 方法:凡是未曾接受過化學治療的廣佈期小細胞肺癌病人,合乎年齡小於70歲,ECOG行為狀態0-3,具有可以測量或評估的病灶,和正常的骨髓、肝、腎功能者,皆可進入本研究,接受ifosfamide每天2.0g/m ,和etoposide每天8Omg/m ,的靜脈注射,連續三天。每四週治療一次,最多治療六次。並於每天給予ifosfamide的同時,4小時,和8小時,靜脈注射mesna每劑400mg/m ,每天三劑,連續三天。 結果:1994年1月到1995年2月間,有10位合乎上述條件的病人接受此治療。10位病人皆為男性,平均年齡63歲。ECOG行為狀態0或l者有5位,2者有4位,3者有l位。10位病人總共接受了45次的化學治療,平均每位4.5次。有6位病人完成了全程6次的化學治療。45坎的化學冶療中有32次(71%)是全量給予,有13次(29%)是給予75%的劑量。於9位可以評估反應的病人中,有8位達到緩解,l位腫瘤大小沒有變化,總反應率是89%。中間存活期是8個月,範圍是0到23個月。第l年和第2年的存活率分別為30%和0%。骨髓抑制是最主要的副作用,尤其是白血球的降低。有5位病人於全部的化學治療程中,白血球曾經低於1,000/mm 。其中有2位發生於第l次化學治療後,並且造成l位病人死於敗血症。其它相關的副作用都不大。 結論:我們的初步臨床經驗顯示ifosfamide是治療小細胞肺癌約有效藥物,合併使用etoposide治療廣佈期小細胞肺癌的病人,總反應率和中間存活期與國外報告相似,但是骨髓抑制的副作用似乎較嚴重。 |
英文摘要 | Background: Ifosfamide, an isomeric analogue of cyclophosphamide, has significant activity against many human tumors including lung cancer, testicular cancer, lymphoma and sarcoma, and may be superior to its analogue. Herein, we report our preliminary experience using ifosfamide and etoposide (IE) combination chemotherapy in previously untreated patients with extensive-disease (ED) small-cell lung cancer (SCLC). Methods: Patients with histologically or cytologically confirmed SCLC, measurable or assessable ED, no previous chemotherapy or thoracic irradiation, younger than 70 years of age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-3, and adequate marrow, liver, and renal functions were eligible for treatment which consisted of ifosfamide 2.0 g/m2/d given intravenously (IV) for 3 days with mesna 400 mg/m2/dose IV administered 0, 4, and 8 hours after the daily administration of ifosfarnide, and etoposide 80 mg/m2/d IV given for 3 days in every 4 weeks for a maximum of 6 cycles. Results: Between January 1994 and February 1995, 10 patients were enrolled into the treatment. All were men with a mean age of 63 +/- 6 years. Five patients had an ECOG PS of 0 or 1, 4 patients of 2, and 1 patient of 3. A total of 45 cycles of IE were given. The mean number of cycles per patient was 4.5 +/- 2.1. Six patients completed 6 courses of therapy. Thirty-two of 45 cycles (71%) of IE were given at full doses, while the remaining 13 cycles (29%) were given at 75% of doses. Nine patients were assessable for response. Eight patients had a partial remission and one patient had stable disease. The overall response rate was 89%. The median survival was 8 months (range, 0 to 23 months) and the median failure-free survival duration was 5.5 months (range, 0 to 18 months). The 1- and 2-year survival rates were 30% and 0%, respectively. Myelotoxicity was the most important toxicity, particularly neutropenia, while thrombocytopenia and anemia were mild. Five of 10 patients (50%) experienced grade 4 neutropenia, which occurred in 2 patients during the first course of IE and resulted in one patient death from early sepsis. Other nonhematologic toxicities were mild. Conclusions: Our preliminary experience demonstrates that ifosfamide is an active drug against SCLC and combination chemotherapy with IE results in similar response rate and median survival, but probably higher myelotoxicity than reported studies in patients with ED SCLC. |
本系統中英文摘要資訊取自各篇刊載內容。